Puma biotechnology press release sales
Puma biotechnology press release sales
Puma biotechnology press release sales
Puma biotechnology press release sales
Puma biotechnology press release sales
Puma biotechnology press release sales

Puma biotechnology press release sales

Puma biotechnology press release sales, HC Wainwright Reiterates Buy Rating for Puma Biotechnology NASDAQ PBYI sales

$54.00

SKU: 7621244

Colour
  • Puma biotechnology hotsell earnings call
  • Securities class action filed against Puma Biotechnology Inc. after disappointing trial
  • Puma Biotechnology Inc. Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 HER2 Mutant HER2 Non Amplified Metastatic Breast Cancer at the 2019 San Antonio Breast...
  • Puma Biotechnology Inc CEO Alan Auerbach Sells 41 396 Shares
Out of stock
Personalised:
: ( x )
Personalisation:
Edit
Remove Personalisation
Frasers Plus

Buy now.

Pay later.

Earn rewards

Representative APR: 29.9% (variable)

Credit subject to status. Terms apply.

Missed payments may affect your credit score

FrasersPlus